Moleculin Biotech (MBRX) shares fell after preliminary efficacy results from the first 45 patients in Part A of its pivotal Phase 2/3 MIRACLE trial did not reach statistical significance. The lack of statistical significance on early data is a clear setback for the trial’s efficacy readout, pressuring near-term sentiment around the program.
Moleculin Biotech (MBRX) shares fell after preliminary efficacy results from the first 45 patients in Part A of its pivotal Phase 2/3 MIRACLE trial did not reach statistical significance. The lack of statistical significance on early data is a clear setback for the trial’s efficacy readout, pressuring near-term sentiment around the program.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately negative
Sentiment Score
-0.45
Ticker Sentiment
